Abbott Laboratories Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Abbott Laboratories on June 8, 2018. The report discloses corporate governance changes effective as of the filing date.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes
- Board Composition: The Board of Directors was expanded from twelve to thirteen members.
- New Director: Michelle A. Kumbier was named to the Board of Directors.
- Bylaw Amendment: Article III, Section 2 of the By-Laws was amended to reflect the new board size.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the professional background and qualifications of the newly appointed director, Michelle A. Kumbier.
- Confirm the effective date of the By-Law amendment regarding board size (June 8, 2018).
- Review the full text of the amended By-Laws (Exhibit 3.1) for any additional governance changes.